{
  "docId": "019de074-2557-77dc-997c-34813158de99",
  "docSlug": "5df8d2698ec92d4699700c9c99264cb6",
  "documentTitle": "Alkermes | Investor Presentation Deck | 28 slides",
  "authorId": "alkermes",
  "authorName": "Alkermes",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 5,
  "pageCount": 28,
  "prevPage": 4,
  "nextPage": 6,
  "slideType": "key_takeaways",
  "function": "prioritize",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-2557-77dc-997c-34813158de99/5",
  "deckHref": "/decks/019de074-2557-77dc-997c-34813158de99",
  "deckJsonHref": "/decks/019de074-2557-77dc-997c-34813158de99.json",
  "deckAnchorHref": "/decks/019de074-2557-77dc-997c-34813158de99#slide-5",
  "components": [
    {
      "bbox": {
        "h": 0.4,
        "w": 0.9,
        "x": 0.05,
        "y": 0.4
      },
      "kind": "list",
      "text": "1. Drive launch of LYBALVI. Continued execution of commercial strategy and investment in DTC campaign. 2. Advance orexin 2 receptor agonist. Establish initial safety and tolerability profile and generate initial clinical proof-of-concept data for ALKS 2680. 3. Separate oncology business. Clarify value proposition for standalone neuroscience and oncology businesses.",
      "attrs": null,
      "subkind": "numbered",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c43035aa-c5d3-424a-b64c-681248332c0d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.05,
        "y": 0.28
      },
      "kind": "paragraph",
      "text": "2023 Business Priorities and Value Drivers",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "50dd4c1d-d21a-4367-9f4f-78465fb6cb15",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.15,
        "x": 0.05,
        "y": 0.88
      },
      "kind": "source-note",
      "text": "DTC: Direct-to-consumer",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6298a827-1401-42e7-86d8-7e9c21b2c647",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.5,
        "x": 0.05,
        "y": 0.12
      },
      "kind": "title",
      "text": "Clear Priorities to Unlock Value in 2023",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "23df91a7-4606-4455-8575-28fa4abfbf98",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "list-presentation",
      "slug": null,
      "matchId": "0b1bde4e-3621-4d49-9fdd-6b058bf9aad4",
      "evidence": "The slide uses a numbered list to present three distinct strategic priorities.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 6,
      "from": 4,
      "beatId": "2be0969e-1dea-4406-978c-4c27055a8edf",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Need",
      "beatSlug": "monroes-sequence-need",
      "evidence": "The deck highlights the need for new treatments in neuroscience and oncology.",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Complication",
      "parentBeatSlug": "complication"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}